TELA Bio is a commercial-stage soft-tissue reconstruction company whose growth story broke in the second quarter. A new chief executive inherited a franchise that still wins hernia procedures on clinical data, yet lost the plastic-surgery volume that had been carrying the mix. The board replaced founder Antony Koblish with Heather Getz days before results, then withdrew full-year revenue guidance. The investment debate is no longer whether OviTex can take share. It is whether a smaller cost base and a repaired commercial model can keep the Perceptive credit facility from accelerating before cash and listing status give out.
Hernia units still rose even as billed revenue lagged, because robotic repair is pulling the mix toward smaller, cheaper implants. Plastic and reconstructive sales fell after a dedicated-representative pilot confused the field force and a handful of high-volume implanters went quiet. International hernia sales kept compounding, and the LiquiFix adjunct stayed small but growing. Gross margin widened on a tariff refund and lighter obsolescence charges, which is helpful and still not the kind of expansion that funds a leveraged balance sheet. Cash ended the quarter at $30 million. First-half operations used $21 million.
Getz has already cut roughly a fifth of the workforce and taken the chief operating and financial officer out of the structure, claiming the reset stretches cash into a later year. Exchange staff has put the listing on a hearing path after the bid-price grace period expired, and a reverse split sits on the October special-meeting agenda. Management still forecasts a probable miss of the minimum-revenue covenant on the $60 million term loan. Does a clinically better mesh franchise survive as a public equity if the commercial reset does not restore growth before the lender and the exchange force the issue?